Can You Still Get Compounded Semaglutide in 2026?

The Short Answer

If you searched this question, you have probably heard that the FDA is "cracking down" on compounded GLP-1s and you want to know whether you can still get yours. Here is the honest answer in three sentences:

• Large-scale compounding is effectively over. Once the FDA declared the semaglutide and tirzepatide shortages resolved, the legal basis that let outsourcing facilities mass-produce compounded versions disappeared.
• Patient-specific compounding still exists. A licensed 503A pharmacy can still make compounded semaglutide for you individually — but generally only when there is a documented clinical need for a formulation the brand product does not offer, not simply to sell a cheaper copy.
• The rules are still moving. In April 2026 the FDA proposed to close the large-scale route permanently. A final decision is still pending, so the landscape can shift again.

The rest of this page explains each of those points, what it means for what you will pay, and how to make sure any program you sign up with is on the right side of the line.

What Actually Changed

Compounded GLP-1s exploded in popularity for one specific reason: the brand-name drugs were on the FDA's official drug shortage list. Federal law lets pharmacies compound copies of a drug while it is in shortage. When that shortage designation goes away, so does most of the legal cover. Here is the verified timeline:

• 2022–2024: Semaglutide (2022) and tirzepatide (2022) were added to the shortage list as demand overwhelmed supply, opening the door to widespread compounding.
• Late 2024 – February 2025: The FDA declared the tirzepatide shortage resolved (2024) and removed semaglutide from the shortage list on February 21, 2025, after the manufacturers ramped up production.
• April 30, 2026: The FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B "bulks list" — finding no ongoing clinical need for outsourcing facilities to compound them from bulk ingredient. The proposal was published in the Federal Register on May 1, 2026.
• June 29, 2026: The public comment window for that proposal closed.
• July 2026 (now): The comment period is over and the FDA has not yet issued a final determination. The proposal is pending.

For the FDA's own explanation of how it is handling compounders as supply stabilizes, see its policy clarification for compounders.

503A vs 503B: Who Can Still Compound

Almost all the confusion about "is it still legal" comes from mixing up two very different kinds of compounding pharmacy. They are governed by separate sections of federal law and the recent FDA actions hit them differently.

	503A Pharmacy	503B Outsourcing Facility
Who they serve	One specific patient at a time, from a prescription	Bulk batches for many patients, no patient-specific prescription needed
Oversight	State boards of pharmacy	Registered and inspected by the FDA
GLP-1 status in 2026	Still permitted — but limited by the "essentially a copy" rule	Effectively closed for GLP-1s; the April 2026 proposal would make it permanent
What "essentially a copy" means	Cannot simply reproduce Wegovy or Zepbound; needs a documented clinical reason for a variation (e.g., a dose not sold commercially, or removing an ingredient a patient reacts to)	Not applicable at scale — the bulk pathway itself is being removed

In plain terms: the era of a telehealth site mass-shipping identical vials of compounded semaglutide as a cut-price Wegovy substitute is ending. A 503A pharmacy making a genuinely patient-specific formulation for a person with a real clinical need is a different, still-legal activity — but it is narrower, more individualized, and not designed to be the cheapest option on the internet.

So Can You Still Get It?

Realistically, there are three paths in 2026, and it is worth being clear-eyed about each:

• Through a legitimate 503A patient-specific program. A prescriber evaluates you, and a licensed pharmacy prepares a formulation tailored to your situation. This is the compliant path, and several telehealth programs still operate this way. Expect real medical intake, not a 60-second quiz.
• Switching to an FDA-approved brand. Increasingly the practical choice: Wegovy, Zepbound, Ozempic, and Mounjaro are guaranteed in quality, and self-pay prices have come down. See our compounded vs brand comparison.
• Grey-market or overseas sellers — avoid these. Sites shipping "semaglutide" with no prescription, no licensed pharmacy, or from overseas are exactly what the FDA is warning about. This is where contamination and dosing errors show up. No price is worth it.

What This Means for Price

The old pitch for compounded GLP-1s was simple: a fraction of the price of Wegovy. That was true during the shortage. In 2026 the picture is more mixed, and we want to be straight with you about it rather than sell you the old story:

• Compounded prices went up, not down, as supply tightened and pharmacies priced in regulatory risk.
• Brand-name prices came down. The oral Wegovy pill and Lilly's direct self-pay program moved the floor for FDA-approved options meaningfully lower than it was a year ago.
• The result: for a lot of people the monthly difference is now modest — and a brand product removes the "will my pharmacy still be allowed to make this next month?" uncertainty entirely.

Compounded can still be the lower-cost choice in some cases, especially for tirzepatide or specific doses. But "much cheaper" is no longer a safe blanket assumption. For current numbers, check our regularly updated GLP-1 price tracker.

How to Tell if a Program Is Still Legitimate

Because the rules tightened, the gap between careful, compliant programs and sketchy ones has widened. Before you hand over payment or medical information, confirm:

For the full safety walkthrough, see our complete guide to compounded GLP-1 medications.

Programs Still Offering Compounded GLP-1

A number of telehealth programs continue to offer compounded semaglutide and tirzepatide through licensed, patient-specific (503A) pharmacies with a prescriber evaluation. Availability and specific offerings change as the regulatory picture evolves, so confirm current details directly with each provider. These are ones we have reviewed:

If Your Prescription Gets Discontinued

If a program stops offering your compounded medication — which is a real possibility as enforcement tightens — do not simply stop cold. Abruptly ending a GLP-1 can bring back appetite and often some weight regain. Instead:

• Ask your prescriber to map your current compounded dose onto the equivalent FDA-approved brand dose.
• Check whether insurance or a manufacturer self-pay program (such as LillyDirect for tirzepatide or NovoCare for semaglutide) makes a brand option affordable.
• Plan the transition so there is no gap in medication, and read our guide on stopping GLP-1s without weight regain if you are considering pausing.

Frequently Asked Questions

This page is reviewed against primary FDA sources and updated as the regulatory situation changes. Last reviewed July 22, 2026. It is educational information, not medical advice — decisions about medication should be made with your healthcare provider.